Dr. Husted's extensive research and teaching experience lies in the areas of business and public policy, business ethics, corporate social responsibility, and corporate sustainability. He has published widely on business topics and is one of the most prolific authors in business ethics. He has published academic articles in journals such as Organization Science, the Strategic Management Journal, the Journal of International Business Studies, the Journal of Policy Analysis and Management, Business Ethics Quarterly, and Business & Society, amongst others. He is a member of the SNII (National System of Researchers), Level III, Conahcyt, and deputy editor of the journal Organization & Environment.

He has had an outstanding academic career as a professor and researcher at Tecnológico de Monterrey since 1990, as well as foreign institutions such as the IE Business School in Madrid and the Schulich Business School at York University in Toronto.

He is currently the Leader of the Research Group (GI) in Conscious Business Development at the Tecnológico de Monterrey Business School and continues his prolific career as Distinguished Professor in Business and Society.
 

• Ph.D., Business Administration, University of California, Berkeley
• Juris Doctor, Brigham Young University
• MBA, Brigham Young University

• Husted, B.; de Sousa-Filho, M. (2019) "Board structure and environmental, social, and governance disclosure in Latin America". Journal of Business Research, 102, 220-227
• Mohammad, S., Husted, B.W. (2019) "Law-abiding organizational climates in developing countries: The role of institutional factors and socially responsible organizational practices". Business Ethics, 28 (4) 476-493
• Bakker,F.; Crane, A.; Henriques, I.; Husted, B. (2019) "Publishing Interdisciplinary Research in Business & Society". Business and Society, 58 (3) 443-452
• Bapuji, Hari, Husted, B.; Jane Lu, and Raza Mir, (2018) "Value creation, appropriation and distribution: How firms contribute to societal economic inequality". Business and Society, 57 (6) 983-1009
• Barnett, M., Henriques, I. & Husted, B. (2018) "Governing the void between stakeholder management and sustainability". Advances in Strategic Management, 38, 121-143

More publications

Dr. Alejandro Madrigal began his medical studies at the Universidad Nacional Autónoma de México (UNAM) and continued his training at some of the world’s top universities. He is currently a Professor of Hematology at UCL, a Faculty of Excellence professor at the Tecnológico de Monterrey, and a Professor Emeritus of the National System of Researchers in Mexico. He was an Honorary Affiliated Physician at the Royal Free Hospital (UK) and UCL Cancer Institute.

He founded and served as the first scientific director of the Anthony Nolan Research Institute in London, which supports people with blood cancer or disorders. He has trained numerous doctors and scientists and has developed multiple Registers for Unrelated Stem Cell Donors (USCD) and cord blood collection centers. His research focuses on how to improve immunotherapy and stem cell transplantation to make cancer cell therapy more accessible, particularly for minorities. He is a Fellow of the Academy of Medical Sciences and a member of the Royal College of Physicians (UK) and holds honorary memberships in the National Academy of Medicine (Mexico) and the Mexican Academy of Sciences.

He has secured multiple grants and has funded students and researchers. He has published over 570 papers, with more than 17,000 citations in journals like Nature and The Lancet. In 2023, he received the Carlos Slim Health Award for Lifetime Achievement in Research for his work on health issues in Latin America. He also holds four honorary doctorates and was appointed an Officer of the Most Excellent Order of the British Empire (OBE) by Queen Elizabeth II in 2022.

Alejandro Madrigal joined Tecnológico de Monterrey as a FEMSA Distinguished Professor in Hematology and Cellular Therapy for the School of Medicine and Health Sciences.

• Postdoctoral studies, Harvard University
• Postdoctoral studies, Stanford University
• Doctoral studies, University College London (UCL)
• Medicine and specialty in Internal Medicine, Universidad Nacional Autónoma de México (UNAM)

• Madrigal, J. A., Chávez, M., & Mayani, H. (2022). Advanced Cell Therapy: Beyond the last Frontier in the Treatment of Cancer. A Historical Perspective Emphasizing the Work of Nobel Prize Laureates. Archives Of Medical Research, 53(8), 747-752. https://doi.org/10.1016/j.arcmed.2022.11.006

• Ros-Soto, J., Snowden, J. A., Szydlo, R., Nicholson, E., Madrigal, A., Easdale, S., Potter, M., Ethell, M., & Anthias, C. (2022). Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. Transplantation And Cellular Therapy, 28(4), 183.e1-183.e8. https://doi.org/10.1016/j.jtct.2022.01.022

• Petersdorf, E. W., Gooley, T., Volt, F., Kenzey, C., Madrigal, A., McKallor, C., Querol, S., Rafii, H., Rocha, V., Tamouza, R., Chabannon, C., Ruggeri, A., & Gluckman, É. (2020). Use of the HLA-B leader to optimize cord blood transplantation. Haematologica, 106(12), 3107-3114. https://doi.org/10.3324/haematol.2020.264424

• Querol, S., Rubinstein, P., & Madrigal, A. (2021). The wider perspective: cord blood banks and their future prospects. British Journal Of Haematology, 195(4), 507-517. https://doi.org/10.1111/bjh.17468

• Wynn, L. A., & Madrigal, A. (2021). Predictive analytics and cord blood banking: toward utilization-based unit selection. Cytotherapy, 23(7), 641-646. https://doi.org/10.1016/j.jcyt.2021.01.002

More information

Dr. Alejandro Madrigal began his medical studies at the Universidad Nacional Autónoma de México (UNAM) and continued his training at some of the world’s top universities. He is currently a Professor of Hematology at UCL, a Faculty of Excellence professor at the Tecnológico de Monterrey, and a Professor Emeritus of the National System of Researchers in Mexico. He was an Honorary Affiliated Physician at the Royal Free Hospital (UK) and UCL Cancer Institute.

He founded and served as the first scientific director of the Anthony Nolan Research Institute in London, which supports people with blood cancer or disorders. He has trained numerous doctors and scientists and has developed multiple Registers for Unrelated Stem Cell Donors (USCD) and cord blood collection centers. His research focuses on how to improve immunotherapy and stem cell transplantation to make cancer cell therapy more accessible, particularly for minorities. He is a Fellow of the Academy of Medical Sciences and a member of the Royal College of Physicians (UK) and holds honorary memberships in the National Academy of Medicine (Mexico) and the Mexican Academy of Sciences.

He has secured multiple grants and has funded students and researchers. He has published over 570 papers, with more than 17,000 citations in journals like Nature and The Lancet. In 2023, he received the Carlos Slim Health Award for Lifetime Achievement in Research for his work on health issues in Latin America. He also holds four honorary doctorates and was appointed an Officer of the Most Excellent Order of the British Empire (OBE) by Queen Elizabeth II in 2022.

Alejandro Madrigal joined Tecnológico de Monterrey as a FEMSA Distinguished Professor in Hematology and Cellular Therapy for the School of Medicine and Health Sciences.

• Postdoctoral studies, Harvard University
• Postdoctoral studies, Stanford University
• Doctoral studies, University College London (UCL)
• Medicine and specialty in Internal Medicine, Universidad Nacional Autónoma de México (UNAM)

• Madrigal, J. A., Chávez, M., & Mayani, H. (2022). Advanced Cell Therapy: Beyond the last Frontier in the Treatment of Cancer. A Historical Perspective Emphasizing the Work of Nobel Prize Laureates. Archives Of Medical Research, 53(8), 747-752. https://doi.org/10.1016/j.arcmed.2022.11.006

• Ros-Soto, J., Snowden, J. A., Szydlo, R., Nicholson, E., Madrigal, A., Easdale, S., Potter, M., Ethell, M., & Anthias, C. (2022). Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. Transplantation And Cellular Therapy, 28(4), 183.e1-183.e8. https://doi.org/10.1016/j.jtct.2022.01.022

• Petersdorf, E. W., Gooley, T., Volt, F., Kenzey, C., Madrigal, A., McKallor, C., Querol, S., Rafii, H., Rocha, V., Tamouza, R., Chabannon, C., Ruggeri, A., & Gluckman, É. (2020). Use of the HLA-B leader to optimize cord blood transplantation. Haematologica, 106(12), 3107-3114. https://doi.org/10.3324/haematol.2020.264424

• Querol, S., Rubinstein, P., & Madrigal, A. (2021). The wider perspective: cord blood banks and their future prospects. British Journal Of Haematology, 195(4), 507-517. https://doi.org/10.1111/bjh.17468

• Wynn, L. A., & Madrigal, A. (2021). Predictive analytics and cord blood banking: toward utilization-based unit selection. Cytotherapy, 23(7), 641-646. https://doi.org/10.1016/j.jcyt.2021.01.002

More information

Dr. Carlos Aguilar is an expert on the pathophysiology, treatment, and management of dyslipidemias and type 2 diabetes in Mexico. He is a surgeon specializing in Internal Medicine and Endocrinology and holds a doctorate in Medical Research. His main contributions include: participating in the identification of new genes involved in the pathophysiology of Familial Combined Hyperlipidemia; being part of the team that conducted the first genome-wide study to identify the genetic variants that modulate plasma lipid levels in Mexicans; and helping identify the R230C variant of the ABC-A1 transporter (a variant specific to Amerindian populations) as a determinant of HDL cholesterol concentrations in Mexicans, among others.

Since 1996, he has been deputy chief of the Department of Endocrinology and Metabolism of the National Institute of Medical Sciences and Nutrition (Mexico) and has been coordinator of the
Ethics Committee of the National Institute of Medical Sciences and Nutrition since 2012. He is also a member of the National Academy of Medicine and has held positions such as director of examinations of the Mexican Board of Endocrinology and president of the Mexican Society of Nutrition and Endocrinology. 

Carlos Aguilar is a Level III researcher with the National System of Researchers in Mexico and a Level F researcher with the National Institutes of Health in the U.S. His scientific output is prolific, with more than 540 articles published in peer-reviewed and/or indexed journals and 66,711 citations. His research focuses on the peculiarities of metabolic diseases in Mexican mestizos, such as the pathophysiology of primary dyslipidemias, the epidemiology of type 2 diabetes, the development of predictive models for type 2 diabetes and its comorbidities, and the characterization of the mechanisms by which certain genetic variants are associated with type 2 diabetes. He received Mexico’s National Science Award in 2018.

Carlos Aguilar joined Tecnológico de Monterrey as Distinguished Visiting Professor in Epidemiology at the School of Medicine and Health Sciences.

• Doctorate in Medical Research, Escuela Superior de Medicina, Instituto Politécnico Nacional
• Research stay at the Division of Atherosclerosis and Lipid Research, Washington University
• Specialty in Endocrinology, Instituto Nacional de la Nutrición
• Specialty in Internal Medicine, Instituto Nacional de la Nutrición
• Medical Surgeon, Universidad Nacional Autónoma de México (UNAM)

• Rojas-Martínez R, Escamilla-Nuñez C, Aguilar-Salinas CA, Castro-Porras L, Romero-Martínez M, Lazcano-Ponce E. Trends in the mortality of diabetes in Mexico from 1998 to 2022: a joinpoint regression and age-period-cohort effect analysis. Public Health. 2023 Dec 5;226:128-137. doi: 10.1016/j.puhe.2023.10.038
• Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, Rivera JA, Romero-Martinez M, Barquera S, Barrientos-Gutiérrez T. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023 Jun 13;65:s163-s168. doi: 10.21149/14832
• Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A, Barrientos-Gutiérrez T, Romero-Martínez M, Aguilar-Salinas C. Tamizaje, prevalencia, diagnóstico previo, tratamiento y control de hipertensión, hipercolesterolemia y diabetes en adultos mexicanos. Ensanut 2022. Salud Publica Mex. 2023 Nov 13;65(6, nov-dic):685-696. doi: 10.21149/15060
• Rivera-Alcántara JA, Esparza-Hurtado N, Galán-Ramírez GA, Cruz-Bautista I, Mehta R, Aguilar-Salinas CA, Martagon AJ. A systematic review of biobanks in Latin America: Strengths and limitations for biomedical research. Int J Biol Markers. 2024 Apr 13:3936155241239672. doi: 10.1177/03936155241239672. PMID: 38613331.
• Vargas-Vázquez A, Fermín-Martínez CA, Antonio-Villa NE, Fernández-Chirino L, Ramírez-García D, Dávila-López G, Díaz-Sánchez JP, Aguilar-Salinas CA, Seiglie JA, Bello-Chavolla OY. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes. Atherosclerosis. 2024 Mar 13:117508. doi: 10.1016/j.atherosclerosis.2024.117508. PMID: 38570208.
• Sohail M, Palma-Martínez MJ, Chong AY, Quinto-Cortés CD, Barberena-Jonas C, Medina-Muñoz SG, Ragsdale A, Delgado-Sánchez G, Cruz-Hervert LP, Ferreyra-Reyes L, Ferreira-Guerrero E, Mongua-Rodríguez N, Canizales-Quintero S, Jimenez-Kaufmann A, Moreno-Macías H, Aguilar-Salinas CA, Auckland K, Cortés A, Acuña-Alonzo V, Gignoux CR, Wojcik GL, Ioannidis AG, Fernández-Valverde SL, Hill AVS, Tusié-Luna MT, Mentzer AJ, Novembre J, García-García L, Moreno-Estrada. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023 Oct 11. doi: 10.1038/s41586-023-06560-0 

More information

Dr. Carlos Aguilar is an expert on the pathophysiology, treatment, and management of dyslipidemias and type 2 diabetes in Mexico. He is a surgeon specializing in Internal Medicine and Endocrinology and holds a doctorate in Medical Research. His main contributions include: participating in the identification of new genes involved in the pathophysiology of Familial Combined Hyperlipidemia; being part of the team that conducted the first genome-wide study to identify the genetic variants that modulate plasma lipid levels in Mexicans; and helping identify the R230C variant of the ABC-A1 transporter (a variant specific to Amerindian populations) as a determinant of HDL cholesterol concentrations in Mexicans, among others.

Since 1996, he has been deputy chief of the Department of Endocrinology and Metabolism of the National Institute of Medical Sciences and Nutrition (Mexico) and has been coordinator of the
Ethics Committee of the National Institute of Medical Sciences and Nutrition since 2012. He is also a member of the National Academy of Medicine and has held positions such as director of examinations of the Mexican Board of Endocrinology and president of the Mexican Society of Nutrition and Endocrinology. 

Carlos Aguilar is a Level III researcher with the National System of Researchers in Mexico and a Level F researcher with the National Institutes of Health in the U.S. His scientific output is prolific, with more than 540 articles published in peer-reviewed and/or indexed journals and 66,711 citations. His research focuses on the peculiarities of metabolic diseases in Mexican mestizos, such as the pathophysiology of primary dyslipidemias, the epidemiology of type 2 diabetes, the development of predictive models for type 2 diabetes and its comorbidities, and the characterization of the mechanisms by which certain genetic variants are associated with type 2 diabetes. He received Mexico’s National Science Award in 2018.

Carlos Aguilar joined Tecnológico de Monterrey as Distinguished Visiting Professor in Epidemiology at the School of Medicine and Health Sciences.

• Doctorate in Medical Research, Escuela Superior de Medicina, Instituto Politécnico Nacional
• Research stay at the Division of Atherosclerosis and Lipid Research, Washington University
• Specialty in Endocrinology, Instituto Nacional de la Nutrición
• Specialty in Internal Medicine, Instituto Nacional de la Nutrición
• Medical Surgeon, Universidad Nacional Autónoma de México (UNAM)

• Rojas-Martínez R, Escamilla-Nuñez C, Aguilar-Salinas CA, Castro-Porras L, Romero-Martínez M, Lazcano-Ponce E. Trends in the mortality of diabetes in Mexico from 1998 to 2022: a joinpoint regression and age-period-cohort effect analysis. Public Health. 2023 Dec 5;226:128-137. doi: 10.1016/j.puhe.2023.10.038
• Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, Rivera JA, Romero-Martinez M, Barquera S, Barrientos-Gutiérrez T. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023 Jun 13;65:s163-s168. doi: 10.21149/14832
• Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A, Barrientos-Gutiérrez T, Romero-Martínez M, Aguilar-Salinas C. Tamizaje, prevalencia, diagnóstico previo, tratamiento y control de hipertensión, hipercolesterolemia y diabetes en adultos mexicanos. Ensanut 2022. Salud Publica Mex. 2023 Nov 13;65(6, nov-dic):685-696. doi: 10.21149/15060
• Rivera-Alcántara JA, Esparza-Hurtado N, Galán-Ramírez GA, Cruz-Bautista I, Mehta R, Aguilar-Salinas CA, Martagon AJ. A systematic review of biobanks in Latin America: Strengths and limitations for biomedical research. Int J Biol Markers. 2024 Apr 13:3936155241239672. doi: 10.1177/03936155241239672. PMID: 38613331.
• Vargas-Vázquez A, Fermín-Martínez CA, Antonio-Villa NE, Fernández-Chirino L, Ramírez-García D, Dávila-López G, Díaz-Sánchez JP, Aguilar-Salinas CA, Seiglie JA, Bello-Chavolla OY. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes. Atherosclerosis. 2024 Mar 13:117508. doi: 10.1016/j.atherosclerosis.2024.117508. PMID: 38570208.
• Sohail M, Palma-Martínez MJ, Chong AY, Quinto-Cortés CD, Barberena-Jonas C, Medina-Muñoz SG, Ragsdale A, Delgado-Sánchez G, Cruz-Hervert LP, Ferreyra-Reyes L, Ferreira-Guerrero E, Mongua-Rodríguez N, Canizales-Quintero S, Jimenez-Kaufmann A, Moreno-Macías H, Aguilar-Salinas CA, Auckland K, Cortés A, Acuña-Alonzo V, Gignoux CR, Wojcik GL, Ioannidis AG, Fernández-Valverde SL, Hill AVS, Tusié-Luna MT, Mentzer AJ, Novembre J, García-García L, Moreno-Estrada. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023 Oct 11. doi: 10.1038/s41586-023-06560-0 

More information

Dr. Armendáriz is recognized globally as one of the leading figures in the field of hepatology and as a pioneer in gene therapy. In addition to his contributions to Tecnológico de Monterrey, Dr. Armendáriz has collaborated for more than 25 years at the University of Guadalajara, where he became Full Professor "C", founder of the Department of Molecular Biology and Genomics, as well as founder and director of the Institute of Molecular Biology in Medicine at said university, one of the first programs in Mexico in what is now called Genomic Medicine. He has also been a visiting professor at the University of Florence, in Italy. 

A Level III Emeritus Researcher of the Mexican National System of Researchers, much of Dr. Armendáriz's research has focused on the cellular and molecular basis of the treatment of liver cirrhosis and renal glomerulosclerosis.

As a result of his research, he has published more than 200 scientific articles, has presented more than 470 papers in national and international congresses, and has played leadership roles in the National Commission for the Human Genome, the Mexican Academy of Science, and the National Academy of Medicine (Mexico).

Among the most relevant recognitions of his career is the National Science Award "Mario Molina", obtained in 2023. 

Dr. Armendáriz joined Tecnológico de Monterrey as a Distinguished Professor in Biomedical Sciences for the School of Medicine and Health Sciences. 

• Post-doctorate in Molecular Biology, University of Tennessee
• PhD Biochemistry, CINVESTAV, Instituto Politécnico Nacional 
• Master in Biochemistry, CINVESTAV, Instituto Politécnico Nacional

Dr. Armendáriz is recognized globally as one of the leading figures in the field of hepatology and as a pioneer in gene therapy. In addition to his contributions to Tecnológico de Monterrey, Dr. Armendáriz has collaborated for more than 25 years at the University of Guadalajara, where he became Full Professor "C", founder of the Department of Molecular Biology and Genomics, as well as founder and director of the Institute of Molecular Biology in Medicine at said university, one of the first programs in Mexico in what is now called Genomic Medicine. He has also been a visiting professor at the University of Florence, in Italy. 

A Level III Emeritus Researcher of the Mexican National System of Researchers, much of Dr. Armendáriz's research has focused on the cellular and molecular basis of the treatment of liver cirrhosis and renal glomerulosclerosis.

As a result of his research, he has published more than 200 scientific articles, has presented more than 470 papers in national and international congresses, and has played leadership roles in the National Commission for the Human Genome, the Mexican Academy of Science, and the National Academy of Medicine (Mexico).

Among the most relevant recognitions of his career is the National Science Award "Mario Molina", obtained in 2023. 

Dr. Armendáriz joined Tecnológico de Monterrey as a Distinguished Professor in Biomedical Sciences for the School of Medicine and Health Sciences. 

• Post-doctorate in Molecular Biology, University of Tennessee
• PhD Biochemistry, CINVESTAV, Instituto Politécnico Nacional 
• Master in Biochemistry, CINVESTAV, Instituto Politécnico Nacional

Dr. Richard Willson has an extensive career at the University of Houston, where he is Huffington-Woestemeyer Professor of Chemical and Biomolecular Engineering and Biochemistry. He is also Co-Principal Investigator of the U.S. FDA's Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC). He has been an affiliate in the Quantitative and Computational Biology program at Baylor College of Medicine since 2008 and a prominent senior affiliate member in the Cancer program at the Houston Methodist Research Institute since 2007. He was theme leader in Diagnostics at the NIH Western Regional Center of Excellence in Biodefense and Emerging Infectious Diseases.

Richard Willson’s work focuses on the development of diagnostics for infectious diseases and metabolic disorders and the development of new pharmaceuticals. He and his research group work on biomolecular recognition using monoclonal antibodies and aptamers. They explore the techniques of expression, mutagenesis, fluorescence anisotropy (kinetics), and titration calorimetry.

In the area of bioseparations, his recent work focuses on antibody purification. In the area of molecular diagnostics and sensors, he is using computer technology to identify viruses vs. human DNA. He is also working on a diagnostic that uses a method similar to glow-in-the-dark materials for easier home-based detection by ultra-sensitive lateral flow immunoassays.

Back in 2012 and due to his expertise in nucleic acid purification, he was selected to serve on the founding Technical Advisory Board of Moderna, Inc., which later developed the mRNA-based vaccine for COVID-19.

Richard Willson joined Tecnológico de Monterrey as a Distinguished Visiting Professor in Biotechnology Engineering for the Institute for Obesity Research and the School of Medicine and Health Sciences.

• Postdoctoral fellow, Biology, Massachusetts Institute of Technology (MIT)
• Ph.D., Chemical Engineering, Massachusetts Institute of Technology (MIT)
• M.Sc., Chemical Engineering, California Institute of Technology (Caltech)
   

• Goux, Heather & Vu, Binh & Wasden, Katherine & Alpadi, Kannan & Kumar, Ajay & Kalra, Bhanu & Savjani, Gopal & Brosamer, Kristen & Kourentzi, Katerina & Willson, Richard. (2023). Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone. Practical Laboratory Medicine. 35. e00314. 10.1016/j.plabm.2023.e00314. 

• Lei, Rongwei & Vu, Binh & Kourentzi, Katerina & Soomro, Sanam & Danthanarayana, Adheesha & Brgoch, Jakoah & Nadimpalli, Suma & Petri, Michelle & Mohan, Chandra & Willson, Richard. (2022). A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Frontiers in Immunology. 13. 10.3389/fimmu.2022.1044743.

• Nandy, Suman & Crum, Mary & Wasden, Katherine & Strych, Ulrich & Goyal, Atul & Maranholkar, Vijay & Mo, William & Vu, Binh & Kourentzi, Katerina & Willson, Richard. (2022). Protein A–Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G. Analytical Biochemistry. 660. 114929. 10.1016/j.ab.2022.114929. 

• Ortiz-Martinez, Margarita & González-González, Mirna & Martagon, Alexandro & Hlavinka, Victoria & Willson, Richard & Rito-Palomares, Marco. (2022). Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Current Diabetes Reports. 22. 10.1007/s11892-022-01453-4. 

• Chavan D, Chen H, Crum M, Vu B, Safari M, Smith M, Vekilov P, Conrad JC, Kourentzi K, Willson RC., "Neutral DNA-avidin nanoparticles as ultrasensitive reporters in immuno-PCR." Analyst. doi: 10.1039/d0an00134a., 2020

More information

Dr. Richard Willson has an extensive career at the University of Houston, where he is Huffington-Woestemeyer Professor of Chemical and Biomolecular Engineering and Biochemistry. He is also Co-Principal Investigator of the U.S. FDA's Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC). He has been an affiliate in the Quantitative and Computational Biology program at Baylor College of Medicine since 2008 and a prominent senior affiliate member in the Cancer program at the Houston Methodist Research Institute since 2007. He was theme leader in Diagnostics at the NIH Western Regional Center of Excellence in Biodefense and Emerging Infectious Diseases.

Richard Willson’s work focuses on the development of diagnostics for infectious diseases and metabolic disorders and the development of new pharmaceuticals. He and his research group work on biomolecular recognition using monoclonal antibodies and aptamers. They explore the techniques of expression, mutagenesis, fluorescence anisotropy (kinetics), and titration calorimetry.

In the area of bioseparations, his recent work focuses on antibody purification. In the area of molecular diagnostics and sensors, he is using computer technology to identify viruses vs. human DNA. He is also working on a diagnostic that uses a method similar to glow-in-the-dark materials for easier home-based detection by ultra-sensitive lateral flow immunoassays.

Back in 2012 and due to his expertise in nucleic acid purification, he was selected to serve on the founding Technical Advisory Board of Moderna, Inc., which later developed the mRNA-based vaccine for COVID-19.

Richard Willson joined Tecnológico de Monterrey as a Distinguished Visiting Professor in Biotechnology Engineering for the Institute for Obesity Research and the School of Medicine and Health Sciences.

• Postdoctoral fellow, Biology, Massachusetts Institute of Technology (MIT)
• Ph.D., Chemical Engineering, Massachusetts Institute of Technology (MIT)
• M.Sc., Chemical Engineering, California Institute of Technology (Caltech)
   

• Goux, Heather & Vu, Binh & Wasden, Katherine & Alpadi, Kannan & Kumar, Ajay & Kalra, Bhanu & Savjani, Gopal & Brosamer, Kristen & Kourentzi, Katerina & Willson, Richard. (2023). Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone. Practical Laboratory Medicine. 35. e00314. 10.1016/j.plabm.2023.e00314. 

• Lei, Rongwei & Vu, Binh & Kourentzi, Katerina & Soomro, Sanam & Danthanarayana, Adheesha & Brgoch, Jakoah & Nadimpalli, Suma & Petri, Michelle & Mohan, Chandra & Willson, Richard. (2022). A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Frontiers in Immunology. 13. 10.3389/fimmu.2022.1044743.

• Nandy, Suman & Crum, Mary & Wasden, Katherine & Strych, Ulrich & Goyal, Atul & Maranholkar, Vijay & Mo, William & Vu, Binh & Kourentzi, Katerina & Willson, Richard. (2022). Protein A–Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G. Analytical Biochemistry. 660. 114929. 10.1016/j.ab.2022.114929. 

• Ortiz-Martinez, Margarita & González-González, Mirna & Martagon, Alexandro & Hlavinka, Victoria & Willson, Richard & Rito-Palomares, Marco. (2022). Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Current Diabetes Reports. 22. 10.1007/s11892-022-01453-4. 

• Chavan D, Chen H, Crum M, Vu B, Safari M, Smith M, Vekilov P, Conrad JC, Kourentzi K, Willson RC., "Neutral DNA-avidin nanoparticles as ultrasensitive reporters in immuno-PCR." Analyst. doi: 10.1039/d0an00134a., 2020

More information